Greenrise Global Brands Inc.’s (formerly AMP Alternative Medical Products Inc.) (Frankfurt: C4T) (ISIN: CA39540L1085) (CSE: XCX), wholly-owned subsidiary, AMP Alternative Medical Products GmbH (“AMP”), a pharmaceutical supplier of medical cannabis products to German pharmacies, announces the launch of a new dronabinol medical cannabis product available in pharmacies beginning in January 2022.
Dronabinol is pure Tetrahydrocannabinol (THC) and is registered as an active pharmaceutical ingredient (API).
AMP’s dronabinol product is “Made in Germany.” It will be offered at a competitive price and completes AMP’s product portfolio supporting any therapy requiring medicinal cannabis products for the growing range of therapies approaches being prescribed by a growing number of doctors.
Dronabinol has been a prominent medical cannabis product in Germany for many years, and it is frequently prescribed by doctors for pain management. In comparison to the procedure of preparing vaporized forms of medicinal cannabis, many patients find dronabinol prescriptions easier to ingest. Doctors believe that the THC concentration of dronabinol is more accurate than that of flowers or extracts, making dosage monitoring easier. Pharmacists use Dronabinol to fill doctor-prescribed medicine prescriptions for patients, usually in the form of drops or solutions.
Dronabinol is Germany’s most often prescribed medical cannabis product, accounting for 35% of all medical cannabis prescriptions and €46.5 million in sales in 2020. In Germany, total medical cannabis sales of reimbursed prescriptions totaled €165 million, accounting for almost 90% of the medical cannabis market in 2020.
AMP’s national sales team is presently receiving training with medical professionals to learn about the benefits of dronabinol for doctors’ patients and prescription preparation methods for pharmacists.
AMP selected a German partner as its dronabinol supplier. Doctors and pharmacists can find more information about the product or order on the AMP website: https://amp-eu.com/doccheck-login
“We are expecting strong sales from this new product as dronabinol is well known to doctors and insurance companies who often reimburse dronabinol prescriptions,” said Dr. Stefan Feuerstein, Managing Director of AMP, and President and Director of Greenrise Global. AMP’s dronabinol product offers the best quality for patients and the best value for pharmacists and insurance companies compared to the limited number of other